Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06472362

Chest CT Biomarkers as Prognostic Predictors in SSc-ILD

The goal of this retrospective observational study is to investigate whether novel imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline predict ILD progression, vasculopathy development, and survival in SSc-ILD.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Bichat-Claude Bernard hospital, Paris, France

Loading trial locations.

About this study

Interstitial lung disease (ILD or lung fibrosis=stiffening of the lungs by scar tissue) develops in over half of patients with systemic sclerosis (SSc). Whilst ILD remains stable in some patients, at least a third have progressively increasing fibrosis. There is a pressing need for accurate indicators that identify a) patients at higher risk of progression, needing immediate treatment to prevent further irreversible ILD; and b) patients at lower risk, not needing treatment.

In this study the prognostic potential and accuracy of machine-learning derived biomarkers to evaluate abnormalities that are difficult to quantify visually will be investigated. Whether novel high resolution computed tomography (HRCT) imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline can predict ILD progression, vasculopathy development, and survival will be investigated in a cohort of approximately 1,000 SSc-ILD patients.

The algorithm scores will be evaluated against survival using Cox proportional hazards modelling, while mixed effects model analysis will be used to assess links with change in lung function: forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLco), and carbon monoxide transfer coefficient (Kco). The airway algorithm measuring traction bronchiectasis (dilatation of the airways due to surrounding fibrosis) may predict worsening of FVC, reflective of ILD progression. The vessel algorithm may predict decline in KCO, a marker of pulmonary vascular involvement. Exploratory analyses evaluating change in HRCT fibrosis extent over time for patients with repeat HRCTs will also be performed, and whether composite outcomes of change in HRCT and lung function variables improve long term outcome prediction and pave the way to their use in clinical trials and routine clinical use. Patients with trivial changes on CT will also be included to assess for very early changes that could be predictive of future decline. These algorithms will be combined with the findings of our previous study, which suggest that a certain type of pattern on CT called UIP predicts shorter survival.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosed with SSc
  • ≥18 years old
  • HRCT between 01/01/1990 and 31/12/2019

Exclusion criteria

  • Patients who do not have SSc
  • <18 years old
  • lack of availability of HRCT imaging data

Treatment and study plan

HRCT biomarkers

Diagnostic Test

HRCT imaging biomarkers of airways, vessels, and overall extent of fibrosis

Primary outcomes

  1. Survival

    Time frame: 15 years

    Transplant-free survival

  2. Pulmonary hypertension

    Time frame: 15 years

    Development of pulmonary hypertension

  3. Decline in FVC

    Time frame: 15 years

    Change in lung function measure FVC

  4. Decline in DLCO

    Time frame: 15 years

    Change in lung function measure DLCO

  5. Decline in KCO

    Time frame: 15 years

    Change in lung function measure KCO

Sponsors and collaborators

Lead sponsor

Royal Brompton & Harefield NHS Foundation Trust

Other

Collaborators

  • Azienda Ospedaliero Universitaria di Sassari
  • Bichat Hospital
  • Hannover Medical School
  • Imperial College London
  • Royal Free and University College Medical School
  • The Leeds Teaching Hospitals NHS Trust
  • University of Siena
  • Università Politecnica delle Marche

Registry information

Official study title

Deep-learning Derived Chest Computed Tomography (CT) Biomarkers as Prognostic Predictors in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Jun 25, 2024
Registry last updated
Sep 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.